How Clonal Hematopoiesis Affects Breast Cancer Outcomes
Official title: Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) on tumor microenvironment and clinical outcomes in triple negative breast cancer
Funded at Vanderbilt University · NIH-11111153 · Data updated 2026-11-12
This study is looking at how certain changes in blood cells, which can happen as we age, might affect the way triple negative breast cancer grows and how well patients do, with the hope of finding better ways to help those diagnosed with this type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $53,373 |
| NIH project number | 5F30CA284523-02 |
| Project ID | NIH-11111153 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those over the age of 70 or who have undergone chemotherapy.
✕Less likely to help
Patients with non-solid tumors or those without any evidence of CHIP may not benefit from this research.
What this research studies
This research investigates the impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) on the tumor microenvironment and clinical outcomes in patients with triple negative breast cancer. It aims to understand how somatic mutations in blood and bone marrow cells, which can occur with age and exposure to stress, influence the behavior of tumors and the immune response. By analyzing clinical sequencing data and patient samples, the study seeks to uncover the relationship between CHIP and patient survival rates, potentially leading to improved management strategies for those affected.
Why it matters
Potential benefit: If successful, this research could lead to better treatment strategies and improved survival outcomes for patients with triple negative breast cancer who have CHIP.
How similar studies have gone: Previous studies have indicated that understanding CHIP's role in cancer can lead to significant insights, suggesting that this research could build on established findings.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Reed, Sarah Camille — Vanderbilt University
- Study coordinator: Reed, Sarah Camille
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.